胸腺肽ɑ1用于失代偿期丙型肝炎肝硬化脾亢进消除后治疗的价值分析

Value of Thymosinɑ1 in the Treatment of Decompensated Hepatitis C Cirrhosis with Hypersplenism After Elimination

目的分析胸腺肽ɑ1用于失代偿期丙型肝炎肝硬化脾亢进消除后治疗的效果。方法选取116例失代偿期丙型肝炎肝硬化患者作为研究对象(2018年1月至2020年1月),所有患者均消除脾亢进并发症,将其随机分成两组,所有患者均给予基础治疗和护理,其中观察组另外采用胸腺肽ɑ1进行治疗。分析胸腺肽ɑ1在治疗中的作用。结果治疗2年后,对照组HCV-RNA水平下降幅度微小,和治疗前比,差异无统计学意义(P>0.05),观察组下降幅度较大,和治疗前以及对照组相比,均有统计学意义(P<0.05);在Child-Pugh评分上,两组经治疗后均得以较大改善(P<0.05),且观察组改善较大(P<0.05);在HCV-RNA转移率上,观察组高于对照组,但差异未达到统计学意义(P>0.05)。治疗2年后,两组的肝功能指标以及肝纤维指标均具有明显改善(P<0.05),在改善程度上,观察组具有明显优势,组间差异有统计学意义(P<0.05)。治疗期间,两组均表现出良好的耐受力,未出现严重不良反应。结论胸腺肽ɑ1可改善失代偿期丙型肝炎肝硬化脾亢进消除后患者的肝功能以及肝纤维化指标,且用药安全。

Objective To analyse the effect of thymosinɑ1 in the treatment of decompensated hepatitis C cirrhosis with hypersplenism after elimination.Methods 116 patients with decompensated hepatitis C cirrhosis from January 2018-January 2020 had eliminated complications of hypersplenism and were divided into 2 groups.All patients were given basic treatment and nursing.The observation group was treated with thymosinɑ1 in addition to analyse the effect of thymosinɑ1.Results After 2 years of treatment,the level of HCV-RNA decreased slightly in the control group and the difference was not statistically significant before treatment(P>0.05).The observation group decreased greatly,it was statistically significant compared with that before treatment and in the control group(P<0.05).On the Child-Pugh score,the two groups were greatly improved after treatment and the observation group improved greatly(P<0.05).On the HCV-RNA transfer rate,the observation group was higher than the control group,but the difference did not reach statistical significance(P>0.05).After 2 years of treatment,the liver function indexes and liver fiber indexes of the two groups were significantly improved(P<0.05),in terms of improvement,the observation group has obvious advantages(P<0.05).During the treatment,the two groups showed good tolerance and no serious adverse reactions occurred.Conclusion Thymosinɑ1 can improve the liver function and liver fibrosis index of patients with decompensated hepatitis C cirrhosis with hypersplenism after elimination,and is safe to use.